AUM LifeTech, Inc. is a US-based preclinical stage biotechnology company leveraging self-delivering RNA targeting technology for therapeutic development. We have developed preclinical assets for lung cancer, Parkinson's disease, and HIV therapy. Our most advanced preclinical asset for lung cancer immunotherapy utilizes RNA targeting approach. AUM LifeTech is actively looking to out-license our preclinical non-viral gene therapy assets and establish strategic alliances with biotech/pharmaceutical companies for therapeutic development.
AUM LifeTech is also looking for co-development opportunities on validated RNA targets (mRNA, miRNA, lncRNA) that can be further investigated for therapeutic development using AUM's self-delivering RNA silencing technology. Antisense technology is a growing alternative to RNAi and CRISPR approaches. We also offer functional genomics, target discovery, target validation, and preclinical research tools (leveraging our RNA silencing technology). Our products are being used globally by biomedical scientists and researchers working on basic, transitional, and preclinical research.
AUM LifeTech, Inc. is presenting as part of the NIH Innovation Zone.